nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—HTR2B—Raloxifene—breast cancer	0.164	0.291	CbGbCtD
Agomelatine—CYP1A2—Anastrozole—breast cancer	0.077	0.136	CbGbCtD
Agomelatine—CYP1A2—Toremifene—breast cancer	0.0705	0.125	CbGbCtD
Agomelatine—CYP2C9—Anastrozole—breast cancer	0.0694	0.123	CbGbCtD
Agomelatine—CYP2C9—Idarubicin—breast cancer	0.0526	0.093	CbGbCtD
Agomelatine—CYP2C9—Capecitabine—breast cancer	0.0288	0.0509	CbGbCtD
Agomelatine—CYP1A2—Tamoxifen—breast cancer	0.0257	0.0455	CbGbCtD
Agomelatine—CYP2C9—Tamoxifen—breast cancer	0.0232	0.041	CbGbCtD
Agomelatine—CYP1A2—Fluorouracil—breast cancer	0.019	0.0335	CbGbCtD
Agomelatine—CYP2C9—Paclitaxel—breast cancer	0.0181	0.0319	CbGbCtD
Agomelatine—CYP2C9—Fluorouracil—breast cancer	0.0171	0.0302	CbGbCtD
Agomelatine—Melatonin—MT3—breast cancer	0.00151	0.171	CrCbGaD
Agomelatine—Melatonin—NQO2—breast cancer	0.00129	0.145	CrCbGaD
Agomelatine—Indomethacin—SLCO1B1—breast cancer	0.000649	0.0734	CrCbGaD
Agomelatine—Nabumetone—PTGS1—breast cancer	0.000646	0.0729	CrCbGaD
Agomelatine—Indomethacin—ABCC1—breast cancer	0.000536	0.0606	CrCbGaD
Agomelatine—Indomethacin—CXCL8—breast cancer	0.000474	0.0536	CrCbGaD
Agomelatine—Midodrine—CYP2D6—breast cancer	0.000451	0.0509	CrCbGaD
Agomelatine—Melatonin—CYP1B1—breast cancer	0.000435	0.0492	CrCbGaD
Agomelatine—Encainide—CYP2D6—breast cancer	0.000402	0.0454	CrCbGaD
Agomelatine—Nabumetone—PTGS2—breast cancer	0.000369	0.0417	CrCbGaD
Agomelatine—Melatonin—CYP19A1—breast cancer	0.00032	0.0361	CrCbGaD
Agomelatine—Naproxen—PTGS1—breast cancer	0.000299	0.0337	CrCbGaD
Agomelatine—Melatonin—ESR1—breast cancer	0.000294	0.0332	CrCbGaD
Agomelatine—Indomethacin—PTGS1—breast cancer	0.000242	0.0273	CrCbGaD
Agomelatine—Melatonin—CYP1A1—breast cancer	0.000235	0.0266	CrCbGaD
Agomelatine—Migraine—Doxorubicin—breast cancer	0.000197	0.000782	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Irinotecan—breast cancer	0.000197	0.000782	CcSEcCtD
Agomelatine—Fatigue—Irinotecan—breast cancer	0.000196	0.000781	CcSEcCtD
Agomelatine—Fatigue—Mitoxantrone—breast cancer	0.000196	0.000781	CcSEcCtD
Agomelatine—Vomiting—Goserelin—breast cancer	0.000196	0.000779	CcSEcCtD
Agomelatine—Paraesthesia—Fluorouracil—breast cancer	0.000196	0.000779	CcSEcCtD
Agomelatine—Pruritus—Vinorelbine—breast cancer	0.000195	0.000777	CcSEcCtD
Agomelatine—Constipation—Mitoxantrone—breast cancer	0.000195	0.000774	CcSEcCtD
Agomelatine—Constipation—Irinotecan—breast cancer	0.000195	0.000774	CcSEcCtD
Agomelatine—Mental disorder—Docetaxel—breast cancer	0.000194	0.000772	CcSEcCtD
Agomelatine—Somnolence—Fluorouracil—breast cancer	0.000194	0.000771	CcSEcCtD
Agomelatine—Nasopharyngitis—Epirubicin—breast cancer	0.000193	0.000768	CcSEcCtD
Agomelatine—Headache—Goserelin—breast cancer	0.000193	0.000768	CcSEcCtD
Agomelatine—Anxiety—Paclitaxel—breast cancer	0.000193	0.000768	CcSEcCtD
Agomelatine—Face oedema—Doxorubicin—breast cancer	0.000193	0.000767	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	0.000192	0.000765	CcSEcCtD
Agomelatine—Dyspepsia—Fluorouracil—breast cancer	0.000192	0.000763	CcSEcCtD
Agomelatine—Nausea—Tamoxifen—breast cancer	0.000192	0.000762	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000192	0.000761	CcSEcCtD
Agomelatine—Fatigue—Gemcitabine—breast cancer	0.000191	0.00076	CcSEcCtD
Agomelatine—Constipation—Gemcitabine—breast cancer	0.00019	0.000754	CcSEcCtD
Agomelatine—Dry mouth—Paclitaxel—breast cancer	0.000189	0.000753	CcSEcCtD
Agomelatine—Asthenia—Thiotepa—breast cancer	0.000189	0.000752	CcSEcCtD
Agomelatine—Diarrhoea—Vinorelbine—breast cancer	0.000189	0.000751	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000188	0.000749	CcSEcCtD
Agomelatine—Mental disorder—Capecitabine—breast cancer	0.000188	0.000747	CcSEcCtD
Agomelatine—Nausea—Melphalan—breast cancer	0.000188	0.000746	CcSEcCtD
Agomelatine—Influenza—Epirubicin—breast cancer	0.000187	0.000742	CcSEcCtD
Agomelatine—Back pain—Docetaxel—breast cancer	0.000187	0.000742	CcSEcCtD
Agomelatine—Pruritus—Thiotepa—breast cancer	0.000187	0.000742	CcSEcCtD
Agomelatine—Gastrointestinal pain—Irinotecan—breast cancer	0.000186	0.00074	CcSEcCtD
Agomelatine—Gastrointestinal pain—Mitoxantrone—breast cancer	0.000186	0.00074	CcSEcCtD
Agomelatine—Infection—Paclitaxel—breast cancer	0.000185	0.000734	CcSEcCtD
Agomelatine—Nausea—Goserelin—breast cancer	0.000183	0.000728	CcSEcCtD
Agomelatine—Dizziness—Vinorelbine—breast cancer	0.000183	0.000726	CcSEcCtD
Agomelatine—Nervous system disorder—Paclitaxel—breast cancer	0.000182	0.000724	CcSEcCtD
Agomelatine—Urticaria—Mitoxantrone—breast cancer	0.000181	0.000719	CcSEcCtD
Agomelatine—Back pain—Capecitabine—breast cancer	0.000181	0.000718	CcSEcCtD
Agomelatine—Diarrhoea—Thiotepa—breast cancer	0.00018	0.000717	CcSEcCtD
Agomelatine—Skin disorder—Paclitaxel—breast cancer	0.00018	0.000717	CcSEcCtD
Agomelatine—Abdominal pain—Mitoxantrone—breast cancer	0.00018	0.000716	CcSEcCtD
Agomelatine—Abdominal pain—Irinotecan—breast cancer	0.00018	0.000716	CcSEcCtD
Agomelatine—Hyperhidrosis—Paclitaxel—breast cancer	0.00018	0.000714	CcSEcCtD
Agomelatine—Nasopharyngitis—Doxorubicin—breast cancer	0.000179	0.000711	CcSEcCtD
Agomelatine—Infestation NOS—Methotrexate—breast cancer	0.000178	0.000707	CcSEcCtD
Agomelatine—Infestation—Methotrexate—breast cancer	0.000178	0.000707	CcSEcCtD
Agomelatine—Depression—Methotrexate—breast cancer	0.000177	0.000705	CcSEcCtD
Agomelatine—Vision blurred—Capecitabine—breast cancer	0.000176	0.0007	CcSEcCtD
Agomelatine—Vomiting—Vinorelbine—breast cancer	0.000176	0.000698	CcSEcCtD
Agomelatine—Tremor—Capecitabine—breast cancer	0.000175	0.000696	CcSEcCtD
Agomelatine—Dizziness—Thiotepa—breast cancer	0.000174	0.000693	CcSEcCtD
Agomelatine—Urticaria—Fluorouracil—breast cancer	0.000173	0.000689	CcSEcCtD
Agomelatine—Headache—Vinorelbine—breast cancer	0.000173	0.000688	CcSEcCtD
Agomelatine—Influenza—Doxorubicin—breast cancer	0.000173	0.000687	CcSEcCtD
Agomelatine—Naproxen—PTGS2—breast cancer	0.000171	0.0193	CrCbGaD
Agomelatine—Weight increased—Epirubicin—breast cancer	0.00017	0.000676	CcSEcCtD
Agomelatine—Weight decreased—Epirubicin—breast cancer	0.000169	0.000672	CcSEcCtD
Agomelatine—Hepatobiliary disease—Methotrexate—breast cancer	0.000168	0.000669	CcSEcCtD
Agomelatine—Insomnia—Paclitaxel—breast cancer	0.000168	0.000668	CcSEcCtD
Agomelatine—Vertigo—Capecitabine—breast cancer	0.000168	0.000667	CcSEcCtD
Agomelatine—Vomiting—Thiotepa—breast cancer	0.000168	0.000667	CcSEcCtD
Agomelatine—Paraesthesia—Paclitaxel—breast cancer	0.000167	0.000663	CcSEcCtD
Agomelatine—Infestation—Epirubicin—breast cancer	0.000166	0.000662	CcSEcCtD
Agomelatine—Infestation NOS—Epirubicin—breast cancer	0.000166	0.000662	CcSEcCtD
Agomelatine—Headache—Thiotepa—breast cancer	0.000165	0.000657	CcSEcCtD
Agomelatine—Somnolence—Paclitaxel—breast cancer	0.000165	0.000656	CcSEcCtD
Agomelatine—Nausea—Vinorelbine—breast cancer	0.000164	0.000652	CcSEcCtD
Agomelatine—Dyspepsia—Paclitaxel—breast cancer	0.000163	0.00065	CcSEcCtD
Agomelatine—Asthenia—Irinotecan—breast cancer	0.000163	0.00065	CcSEcCtD
Agomelatine—Asthenia—Mitoxantrone—breast cancer	0.000163	0.00065	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000163	0.000648	CcSEcCtD
Agomelatine—Jaundice—Epirubicin—breast cancer	0.000162	0.000645	CcSEcCtD
Agomelatine—Dry mouth—Docetaxel—breast cancer	0.000161	0.000638	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Paclitaxel—breast cancer	0.00016	0.000637	CcSEcCtD
Agomelatine—Fatigue—Paclitaxel—breast cancer	0.00016	0.000637	CcSEcCtD
Agomelatine—Hepatitis—Methotrexate—breast cancer	0.00016	0.000635	CcSEcCtD
Agomelatine—Asthenia—Gemcitabine—breast cancer	0.000159	0.000633	CcSEcCtD
Agomelatine—Constipation—Paclitaxel—breast cancer	0.000159	0.000631	CcSEcCtD
Agomelatine—Anxiety—Capecitabine—breast cancer	0.000158	0.00063	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000158	0.000628	CcSEcCtD
Agomelatine—Hepatobiliary disease—Epirubicin—breast cancer	0.000157	0.000626	CcSEcCtD
Agomelatine—Weight increased—Doxorubicin—breast cancer	0.000157	0.000625	CcSEcCtD
Agomelatine—Pruritus—Gemcitabine—breast cancer	0.000157	0.000624	CcSEcCtD
Agomelatine—Nausea—Thiotepa—breast cancer	0.000157	0.000623	CcSEcCtD
Agomelatine—Infection—Docetaxel—breast cancer	0.000156	0.000622	CcSEcCtD
Agomelatine—Weight decreased—Doxorubicin—breast cancer	0.000156	0.000621	CcSEcCtD
Agomelatine—Diarrhoea—Irinotecan—breast cancer	0.000156	0.000619	CcSEcCtD
Agomelatine—Diarrhoea—Mitoxantrone—breast cancer	0.000156	0.000619	CcSEcCtD
Agomelatine—Dry mouth—Capecitabine—breast cancer	0.000155	0.000618	CcSEcCtD
Agomelatine—Nervous system disorder—Docetaxel—breast cancer	0.000154	0.000614	CcSEcCtD
Agomelatine—Pruritus—Fluorouracil—breast cancer	0.000154	0.000613	CcSEcCtD
Agomelatine—Infestation NOS—Doxorubicin—breast cancer	0.000154	0.000612	CcSEcCtD
Agomelatine—Infestation—Doxorubicin—breast cancer	0.000154	0.000612	CcSEcCtD
Agomelatine—Skin disorder—Docetaxel—breast cancer	0.000153	0.000608	CcSEcCtD
Agomelatine—Naproxen—ALB—breast cancer	0.000152	0.0172	CrCbGaD
Agomelatine—Gastrointestinal pain—Paclitaxel—breast cancer	0.000152	0.000604	CcSEcCtD
Agomelatine—Diarrhoea—Gemcitabine—breast cancer	0.000152	0.000603	CcSEcCtD
Agomelatine—Infection—Capecitabine—breast cancer	0.000151	0.000602	CcSEcCtD
Agomelatine—Dizziness—Irinotecan—breast cancer	0.000151	0.000599	CcSEcCtD
Agomelatine—Jaundice—Doxorubicin—breast cancer	0.00015	0.000597	CcSEcCtD
Agomelatine—Nervous system disorder—Capecitabine—breast cancer	0.000149	0.000594	CcSEcCtD
Agomelatine—Hepatitis—Epirubicin—breast cancer	0.000149	0.000594	CcSEcCtD
Agomelatine—Eye disorder—Methotrexate—breast cancer	0.000149	0.000593	CcSEcCtD
Agomelatine—Diarrhoea—Fluorouracil—breast cancer	0.000149	0.000593	CcSEcCtD
Agomelatine—Tinnitus—Methotrexate—breast cancer	0.000149	0.000592	CcSEcCtD
Agomelatine—Skin disorder—Capecitabine—breast cancer	0.000148	0.000589	CcSEcCtD
Agomelatine—Urticaria—Paclitaxel—breast cancer	0.000148	0.000587	CcSEcCtD
Agomelatine—Hyperhidrosis—Capecitabine—breast cancer	0.000147	0.000586	CcSEcCtD
Agomelatine—Connective tissue disorder—Epirubicin—breast cancer	0.000147	0.000584	CcSEcCtD
Agomelatine—Abdominal pain—Paclitaxel—breast cancer	0.000147	0.000584	CcSEcCtD
Agomelatine—Hepatobiliary disease—Doxorubicin—breast cancer	0.000146	0.000579	CcSEcCtD
Agomelatine—Vomiting—Irinotecan—breast cancer	0.000145	0.000576	CcSEcCtD
Agomelatine—Vomiting—Mitoxantrone—breast cancer	0.000145	0.000576	CcSEcCtD
Agomelatine—Dizziness—Fluorouracil—breast cancer	0.000144	0.000573	CcSEcCtD
Agomelatine—Headache—Irinotecan—breast cancer	0.000143	0.000567	CcSEcCtD
Agomelatine—Headache—Mitoxantrone—breast cancer	0.000143	0.000567	CcSEcCtD
Agomelatine—Insomnia—Docetaxel—breast cancer	0.000142	0.000566	CcSEcCtD
Agomelatine—Paraesthesia—Docetaxel—breast cancer	0.000141	0.000562	CcSEcCtD
Agomelatine—Vomiting—Gemcitabine—breast cancer	0.000141	0.000561	CcSEcCtD
Agomelatine—Somnolence—Docetaxel—breast cancer	0.00014	0.000556	CcSEcCtD
Agomelatine—Mental disorder—Methotrexate—breast cancer	0.00014	0.000556	CcSEcCtD
Agomelatine—Eye disorder—Epirubicin—breast cancer	0.00014	0.000555	CcSEcCtD
Agomelatine—Tinnitus—Epirubicin—breast cancer	0.000139	0.000554	CcSEcCtD
Agomelatine—Headache—Gemcitabine—breast cancer	0.000139	0.000552	CcSEcCtD
Agomelatine—Vomiting—Fluorouracil—breast cancer	0.000139	0.000551	CcSEcCtD
Agomelatine—Dyspepsia—Docetaxel—breast cancer	0.000139	0.000551	CcSEcCtD
Agomelatine—Indomethacin—PTGS2—breast cancer	0.000138	0.0156	CrCbGaD
Agomelatine—Hepatitis—Doxorubicin—breast cancer	0.000138	0.00055	CcSEcCtD
Agomelatine—Insomnia—Capecitabine—breast cancer	0.000138	0.000548	CcSEcCtD
Agomelatine—Paraesthesia—Capecitabine—breast cancer	0.000137	0.000544	CcSEcCtD
Agomelatine—Headache—Fluorouracil—breast cancer	0.000137	0.000543	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Docetaxel—breast cancer	0.000136	0.00054	CcSEcCtD
Agomelatine—Connective tissue disorder—Doxorubicin—breast cancer	0.000136	0.00054	CcSEcCtD
Agomelatine—Fatigue—Docetaxel—breast cancer	0.000136	0.00054	CcSEcCtD
Agomelatine—Nausea—Mitoxantrone—breast cancer	0.000135	0.000538	CcSEcCtD
Agomelatine—Nausea—Irinotecan—breast cancer	0.000135	0.000538	CcSEcCtD
Agomelatine—Constipation—Docetaxel—breast cancer	0.000135	0.000535	CcSEcCtD
Agomelatine—Back pain—Methotrexate—breast cancer	0.000134	0.000535	CcSEcCtD
Agomelatine—Dyspepsia—Capecitabine—breast cancer	0.000134	0.000533	CcSEcCtD
Agomelatine—Asthenia—Paclitaxel—breast cancer	0.000133	0.00053	CcSEcCtD
Agomelatine—Nausea—Gemcitabine—breast cancer	0.000132	0.000524	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Capecitabine—breast cancer	0.000132	0.000523	CcSEcCtD
Agomelatine—Fatigue—Capecitabine—breast cancer	0.000131	0.000522	CcSEcCtD
Agomelatine—Pruritus—Paclitaxel—breast cancer	0.000131	0.000522	CcSEcCtD
Agomelatine—Vision blurred—Methotrexate—breast cancer	0.000131	0.000521	CcSEcCtD
Agomelatine—Mental disorder—Epirubicin—breast cancer	0.000131	0.000521	CcSEcCtD
Agomelatine—Constipation—Capecitabine—breast cancer	0.00013	0.000518	CcSEcCtD
Agomelatine—Nausea—Fluorouracil—breast cancer	0.00013	0.000515	CcSEcCtD
Agomelatine—Eye disorder—Doxorubicin—breast cancer	0.000129	0.000514	CcSEcCtD
Agomelatine—Tinnitus—Doxorubicin—breast cancer	0.000129	0.000513	CcSEcCtD
Agomelatine—Gastrointestinal pain—Docetaxel—breast cancer	0.000129	0.000512	CcSEcCtD
Agomelatine—Diarrhoea—Paclitaxel—breast cancer	0.000127	0.000505	CcSEcCtD
Agomelatine—Back pain—Epirubicin—breast cancer	0.000126	0.0005	CcSEcCtD
Agomelatine—Vertigo—Methotrexate—breast cancer	0.000125	0.000497	CcSEcCtD
Agomelatine—Gastrointestinal pain—Capecitabine—breast cancer	0.000125	0.000495	CcSEcCtD
Agomelatine—Abdominal pain—Docetaxel—breast cancer	0.000124	0.000495	CcSEcCtD
Agomelatine—Indomethacin—ALB—breast cancer	0.000123	0.0139	CrCbGaD
Agomelatine—Dizziness—Paclitaxel—breast cancer	0.000123	0.000488	CcSEcCtD
Agomelatine—Vision blurred—Epirubicin—breast cancer	0.000123	0.000487	CcSEcCtD
Agomelatine—Mental disorder—Doxorubicin—breast cancer	0.000121	0.000482	CcSEcCtD
Agomelatine—Urticaria—Capecitabine—breast cancer	0.000121	0.000481	CcSEcCtD
Agomelatine—Abdominal pain—Capecitabine—breast cancer	0.00012	0.000479	CcSEcCtD
Agomelatine—Agitation—Epirubicin—breast cancer	0.00012	0.000475	CcSEcCtD
Agomelatine—Vomiting—Paclitaxel—breast cancer	0.000118	0.000469	CcSEcCtD
Agomelatine—Indomethacin—ABCB1—breast cancer	0.000118	0.0133	CrCbGaD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000118	0.000467	CcSEcCtD
Agomelatine—Vertigo—Epirubicin—breast cancer	0.000117	0.000465	CcSEcCtD
Agomelatine—Back pain—Doxorubicin—breast cancer	0.000116	0.000463	CcSEcCtD
Agomelatine—Headache—Paclitaxel—breast cancer	0.000116	0.000463	CcSEcCtD
Agomelatine—Vision blurred—Doxorubicin—breast cancer	0.000113	0.000451	CcSEcCtD
Agomelatine—Asthenia—Docetaxel—breast cancer	0.000113	0.000449	CcSEcCtD
Agomelatine—Infection—Methotrexate—breast cancer	0.000113	0.000448	CcSEcCtD
Agomelatine—Pruritus—Docetaxel—breast cancer	0.000111	0.000443	CcSEcCtD
Agomelatine—Nervous system disorder—Methotrexate—breast cancer	0.000111	0.000442	CcSEcCtD
Agomelatine—Agitation—Doxorubicin—breast cancer	0.000111	0.00044	CcSEcCtD
Agomelatine—Anxiety—Epirubicin—breast cancer	0.00011	0.000439	CcSEcCtD
Agomelatine—Nausea—Paclitaxel—breast cancer	0.00011	0.000439	CcSEcCtD
Agomelatine—Skin disorder—Methotrexate—breast cancer	0.00011	0.000438	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.00011	0.000437	CcSEcCtD
Agomelatine—Hyperhidrosis—Methotrexate—breast cancer	0.00011	0.000436	CcSEcCtD
Agomelatine—Asthenia—Capecitabine—breast cancer	0.000109	0.000435	CcSEcCtD
Agomelatine—Dry mouth—Epirubicin—breast cancer	0.000108	0.000431	CcSEcCtD
Agomelatine—Vertigo—Doxorubicin—breast cancer	0.000108	0.00043	CcSEcCtD
Agomelatine—Pruritus—Capecitabine—breast cancer	0.000108	0.000429	CcSEcCtD
Agomelatine—Diarrhoea—Docetaxel—breast cancer	0.000108	0.000428	CcSEcCtD
Agomelatine—Infection—Epirubicin—breast cancer	0.000105	0.000419	CcSEcCtD
Agomelatine—Diarrhoea—Capecitabine—breast cancer	0.000104	0.000415	CcSEcCtD
Agomelatine—Nervous system disorder—Epirubicin—breast cancer	0.000104	0.000414	CcSEcCtD
Agomelatine—Dizziness—Docetaxel—breast cancer	0.000104	0.000414	CcSEcCtD
Agomelatine—Skin disorder—Epirubicin—breast cancer	0.000103	0.00041	CcSEcCtD
Agomelatine—Hyperhidrosis—Epirubicin—breast cancer	0.000103	0.000408	CcSEcCtD
Agomelatine—Insomnia—Methotrexate—breast cancer	0.000103	0.000408	CcSEcCtD
Agomelatine—Anxiety—Doxorubicin—breast cancer	0.000102	0.000406	CcSEcCtD
Agomelatine—Paraesthesia—Methotrexate—breast cancer	0.000102	0.000405	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.000102	0.000405	CcSEcCtD
Agomelatine—Somnolence—Methotrexate—breast cancer	0.000101	0.000401	CcSEcCtD
Agomelatine—Dizziness—Capecitabine—breast cancer	0.000101	0.000401	CcSEcCtD
Agomelatine—Dry mouth—Doxorubicin—breast cancer	0.0001	0.000398	CcSEcCtD
Agomelatine—Vomiting—Docetaxel—breast cancer	0.0001	0.000398	CcSEcCtD
Agomelatine—Dyspepsia—Methotrexate—breast cancer	9.99e-05	0.000397	CcSEcCtD
Agomelatine—Headache—Docetaxel—breast cancer	9.86e-05	0.000392	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Methotrexate—breast cancer	9.8e-05	0.000389	CcSEcCtD
Agomelatine—Fatigue—Methotrexate—breast cancer	9.78e-05	0.000389	CcSEcCtD
Agomelatine—Infection—Doxorubicin—breast cancer	9.76e-05	0.000388	CcSEcCtD
Agomelatine—Vomiting—Capecitabine—breast cancer	9.69e-05	0.000385	CcSEcCtD
Agomelatine—Nervous system disorder—Doxorubicin—breast cancer	9.64e-05	0.000383	CcSEcCtD
Agomelatine—Insomnia—Epirubicin—breast cancer	9.6e-05	0.000382	CcSEcCtD
Agomelatine—Headache—Capecitabine—breast cancer	9.55e-05	0.00038	CcSEcCtD
Agomelatine—Skin disorder—Doxorubicin—breast cancer	9.54e-05	0.000379	CcSEcCtD
Agomelatine—Paraesthesia—Epirubicin—breast cancer	9.53e-05	0.000379	CcSEcCtD
Agomelatine—Hyperhidrosis—Doxorubicin—breast cancer	9.5e-05	0.000378	CcSEcCtD
Agomelatine—Somnolence—Epirubicin—breast cancer	9.44e-05	0.000375	CcSEcCtD
Agomelatine—Nausea—Docetaxel—breast cancer	9.35e-05	0.000372	CcSEcCtD
Agomelatine—Dyspepsia—Epirubicin—breast cancer	9.35e-05	0.000372	CcSEcCtD
Agomelatine—Gastrointestinal pain—Methotrexate—breast cancer	9.28e-05	0.000369	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Epirubicin—breast cancer	9.17e-05	0.000364	CcSEcCtD
Agomelatine—Fatigue—Epirubicin—breast cancer	9.15e-05	0.000364	CcSEcCtD
Agomelatine—Constipation—Epirubicin—breast cancer	9.08e-05	0.000361	CcSEcCtD
Agomelatine—Nausea—Capecitabine—breast cancer	9.05e-05	0.00036	CcSEcCtD
Agomelatine—Urticaria—Methotrexate—breast cancer	9.01e-05	0.000358	CcSEcCtD
Agomelatine—Abdominal pain—Methotrexate—breast cancer	8.97e-05	0.000357	CcSEcCtD
Agomelatine—Insomnia—Doxorubicin—breast cancer	8.89e-05	0.000353	CcSEcCtD
Agomelatine—Paraesthesia—Doxorubicin—breast cancer	8.82e-05	0.000351	CcSEcCtD
Agomelatine—Somnolence—Doxorubicin—breast cancer	8.73e-05	0.000347	CcSEcCtD
Agomelatine—Gastrointestinal pain—Epirubicin—breast cancer	8.68e-05	0.000345	CcSEcCtD
Agomelatine—Dyspepsia—Doxorubicin—breast cancer	8.65e-05	0.000344	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Doxorubicin—breast cancer	8.48e-05	0.000337	CcSEcCtD
Agomelatine—Fatigue—Doxorubicin—breast cancer	8.47e-05	0.000337	CcSEcCtD
Agomelatine—Urticaria—Epirubicin—breast cancer	8.44e-05	0.000335	CcSEcCtD
Agomelatine—Constipation—Doxorubicin—breast cancer	8.4e-05	0.000334	CcSEcCtD
Agomelatine—Abdominal pain—Epirubicin—breast cancer	8.39e-05	0.000334	CcSEcCtD
Agomelatine—Asthenia—Methotrexate—breast cancer	8.14e-05	0.000324	CcSEcCtD
Agomelatine—Gastrointestinal pain—Doxorubicin—breast cancer	8.03e-05	0.000319	CcSEcCtD
Agomelatine—Pruritus—Methotrexate—breast cancer	8.03e-05	0.000319	CcSEcCtD
Agomelatine—Urticaria—Doxorubicin—breast cancer	7.81e-05	0.00031	CcSEcCtD
Agomelatine—Abdominal pain—Doxorubicin—breast cancer	7.77e-05	0.000309	CcSEcCtD
Agomelatine—Diarrhoea—Methotrexate—breast cancer	7.76e-05	0.000309	CcSEcCtD
Agomelatine—Asthenia—Epirubicin—breast cancer	7.62e-05	0.000303	CcSEcCtD
Agomelatine—Pruritus—Epirubicin—breast cancer	7.51e-05	0.000299	CcSEcCtD
Agomelatine—Dizziness—Methotrexate—breast cancer	7.5e-05	0.000298	CcSEcCtD
Agomelatine—Diarrhoea—Epirubicin—breast cancer	7.27e-05	0.000289	CcSEcCtD
Agomelatine—Vomiting—Methotrexate—breast cancer	7.21e-05	0.000287	CcSEcCtD
Agomelatine—Headache—Methotrexate—breast cancer	7.11e-05	0.000283	CcSEcCtD
Agomelatine—Asthenia—Doxorubicin—breast cancer	7.05e-05	0.00028	CcSEcCtD
Agomelatine—Dizziness—Epirubicin—breast cancer	7.02e-05	0.000279	CcSEcCtD
Agomelatine—Pruritus—Doxorubicin—breast cancer	6.95e-05	0.000276	CcSEcCtD
Agomelatine—Vomiting—Epirubicin—breast cancer	6.75e-05	0.000268	CcSEcCtD
Agomelatine—Nausea—Methotrexate—breast cancer	6.74e-05	0.000268	CcSEcCtD
Agomelatine—Diarrhoea—Doxorubicin—breast cancer	6.72e-05	0.000267	CcSEcCtD
Agomelatine—Headache—Epirubicin—breast cancer	6.65e-05	0.000264	CcSEcCtD
Agomelatine—Dizziness—Doxorubicin—breast cancer	6.5e-05	0.000258	CcSEcCtD
Agomelatine—Nausea—Epirubicin—breast cancer	6.31e-05	0.000251	CcSEcCtD
Agomelatine—Vomiting—Doxorubicin—breast cancer	6.25e-05	0.000248	CcSEcCtD
Agomelatine—Headache—Doxorubicin—breast cancer	6.15e-05	0.000245	CcSEcCtD
Agomelatine—Nausea—Doxorubicin—breast cancer	5.84e-05	0.000232	CcSEcCtD
Agomelatine—CYP1A2—Metabolism—NAT2—breast cancer	1.09e-05	6.26e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HIF1A—breast cancer	1.08e-05	6.19e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NCOA3—breast cancer	1.07e-05	6.14e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SMAD4—breast cancer	1.06e-05	6.11e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC2A2—breast cancer	1.06e-05	6.09e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IGF1R—breast cancer	1.05e-05	6.07e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—LEP—breast cancer	1.05e-05	6.04e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—CXCL8—breast cancer	1.05e-05	6.04e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	1.05e-05	6.03e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CAV1—breast cancer	1.04e-05	5.99e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CPT1A—breast cancer	1.04e-05	5.97e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—MTR—breast cancer	1.04e-05	5.97e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ABCG2—breast cancer	1.04e-05	5.97e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HES1—breast cancer	1.04e-05	5.96e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PLA2G4A—breast cancer	1.03e-05	5.93e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NCOR1—breast cancer	1.03e-05	5.93e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KDR—breast cancer	1.03e-05	5.92e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CSF2—breast cancer	1.02e-05	5.86e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FGF1—breast cancer	1.02e-05	5.86e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HPGDS—breast cancer	1.02e-05	5.86e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—RAF1—breast cancer	1.02e-05	5.85e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HBA1—breast cancer	1.01e-05	5.82e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NRG1—breast cancer	1.01e-05	5.82e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—H2AFX—breast cancer	1e-05	5.78e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—IL2—breast cancer	1e-05	5.77e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ESR1—breast cancer	1e-05	5.77e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—E2F1—breast cancer	9.96e-06	5.73e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CB—breast cancer	9.91e-06	5.71e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—FN1—breast cancer	9.9e-06	5.7e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTT1—breast cancer	9.86e-06	5.68e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ACHE—breast cancer	9.86e-06	5.68e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—breast cancer	9.83e-06	5.66e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NFKBIA—breast cancer	9.78e-06	5.63e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NOTCH1—breast cancer	9.69e-06	5.58e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SPP1—breast cancer	9.57e-06	5.51e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—DPYD—breast cancer	9.53e-06	5.49e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—MED12—breast cancer	9.53e-06	5.49e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CXCL8—breast cancer	9.53e-06	5.49e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—APC—breast cancer	9.47e-06	5.45e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KIT—breast cancer	9.47e-06	5.45e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CG—breast cancer	9.47e-06	5.45e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ERBB3—breast cancer	9.47e-06	5.45e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FGFR2—breast cancer	9.45e-06	5.44e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ALDOA—breast cancer	9.38e-06	5.4e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EGF—breast cancer	9.36e-06	5.39e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP17A1—breast cancer	9.34e-06	5.38e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ENO1—breast cancer	9.24e-06	5.32e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTGS1—breast cancer	9.24e-06	5.32e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	9.21e-06	5.3e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOA3—breast cancer	9.11e-06	5.24e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL2—breast cancer	9.11e-06	5.24e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—breast cancer	9.09e-06	5.23e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—MAPK3—breast cancer	9.07e-06	5.22e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TERT—breast cancer	9.07e-06	5.22e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP2D6—breast cancer	9.06e-06	5.22e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC2A2—breast cancer	9.05e-06	5.21e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	8.95e-06	5.15e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—BRAF—breast cancer	8.91e-06	5.13e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NCOA2—breast cancer	8.9e-06	5.12e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ABCG2—breast cancer	8.86e-06	5.1e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CPT1A—breast cancer	8.86e-06	5.1e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—MTR—breast cancer	8.86e-06	5.1e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FGFR1—breast cancer	8.81e-06	5.07e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HPGDS—breast cancer	8.69e-06	5e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HIF1A—breast cancer	8.68e-06	5e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IGF1—breast cancer	8.67e-06	4.99e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKT2—breast cancer	8.67e-06	4.99e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HBA1—breast cancer	8.64e-06	4.97e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—EGFR—breast cancer	8.63e-06	4.97e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—FASN—breast cancer	8.63e-06	4.97e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—BCHE—breast cancer	8.59e-06	4.95e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC5A5—breast cancer	8.49e-06	4.89e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—LEP—breast cancer	8.47e-06	4.88e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTT1—breast cancer	8.43e-06	4.85e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ACHE—breast cancer	8.43e-06	4.85e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CAV1—breast cancer	8.39e-06	4.83e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CD—breast cancer	8.33e-06	4.8e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KDR—breast cancer	8.3e-06	4.78e-05	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CA—breast cancer	8.25e-06	4.75e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SERPINE1—breast cancer	8.24e-06	4.74e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC2A1—breast cancer	8.2e-06	4.72e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NQO1—breast cancer	8.2e-06	4.72e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KRAS—breast cancer	8.15e-06	4.69e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ESR1—breast cancer	8.09e-06	4.66e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	8.03e-06	4.62e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP3A4—breast cancer	7.99e-06	4.6e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FN1—breast cancer	7.99e-06	4.6e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP17A1—breast cancer	7.98e-06	4.59e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	7.95e-06	4.58e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ENO1—breast cancer	7.9e-06	4.55e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTGS1—breast cancer	7.9e-06	4.55e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NFKBIA—breast cancer	7.89e-06	4.54e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	7.87e-06	4.53e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NOS3—breast cancer	7.86e-06	4.53e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP1B1—breast cancer	7.86e-06	4.52e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NOTCH1—breast cancer	7.82e-06	4.5e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—breast cancer	7.77e-06	4.47e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP2D6—breast cancer	7.75e-06	4.46e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HSP90AA1—breast cancer	7.71e-06	4.44e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KIT—breast cancer	7.64e-06	4.4e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CG—breast cancer	7.64e-06	4.4e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—APC—breast cancer	7.64e-06	4.4e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOA2—breast cancer	7.6e-06	4.38e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EGF—breast cancer	7.56e-06	4.35e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NCOA1—breast cancer	7.5e-06	4.32e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CA—breast cancer	7.49e-06	4.31e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MDM2—breast cancer	7.46e-06	4.3e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—RAF1—breast cancer	7.44e-06	4.28e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—RELA—breast cancer	7.4e-06	4.26e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—STK11—breast cancer	7.39e-06	4.25e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP19A1—breast cancer	7.39e-06	4.25e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—FASN—breast cancer	7.37e-06	4.25e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ERBB2—breast cancer	7.36e-06	4.24e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—BCHE—breast cancer	7.34e-06	4.23e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MAPK3—breast cancer	7.32e-06	4.21e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CB—breast cancer	7.26e-06	4.18e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MTOR—breast cancer	7.26e-06	4.18e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC5A5—breast cancer	7.25e-06	4.18e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—BRAF—breast cancer	7.18e-06	4.14e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NQO1—breast cancer	7e-06	4.03e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC2A1—breast cancer	7e-06	4.03e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IGF1—breast cancer	7e-06	4.03e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKT2—breast cancer	6.99e-06	4.03e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CXCL8—breast cancer	6.98e-06	4.02e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—EGFR—breast cancer	6.96e-06	4.01e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	6.94e-06	3.99e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—HRAS—breast cancer	6.93e-06	3.99e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—COMT—breast cancer	6.87e-06	3.96e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	6.86e-06	3.95e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTP1—breast cancer	6.84e-06	3.94e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP3A4—breast cancer	6.83e-06	3.93e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN1B—breast cancer	6.81e-06	3.92e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	6.8e-06	3.91e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HMOX1—breast cancer	6.74e-06	3.88e-05	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—AKT1—breast cancer	6.74e-06	3.88e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ITPR1—breast cancer	6.73e-06	3.87e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CD—breast cancer	6.72e-06	3.87e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP1B1—breast cancer	6.72e-06	3.87e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CASP3—breast cancer	6.68e-06	3.84e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL2—breast cancer	6.67e-06	3.84e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CA—breast cancer	6.66e-06	3.83e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SERPINE1—breast cancer	6.65e-06	3.83e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL6—breast cancer	6.63e-06	3.82e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HSP90AA1—breast cancer	6.59e-06	3.79e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KRAS—breast cancer	6.58e-06	3.79e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCND1—breast cancer	6.5e-06	3.74e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JUN—breast cancer	6.49e-06	3.73e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ABCB1—breast cancer	6.47e-06	3.73e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CTNNB1—breast cancer	6.44e-06	3.71e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOA1—breast cancer	6.41e-06	3.69e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TYMS—breast cancer	6.36e-06	3.66e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NOS3—breast cancer	6.34e-06	3.65e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP19A1—breast cancer	6.31e-06	3.64e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—STK11—breast cancer	6.31e-06	3.64e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MMP9—breast cancer	6.31e-06	3.63e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN1A—breast cancer	6.29e-06	3.62e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NCOR1—breast cancer	6.28e-06	3.62e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTM1—breast cancer	6.28e-06	3.62e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PLA2G4A—breast cancer	6.28e-06	3.62e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTEN—breast cancer	6.27e-06	3.61e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK8—breast cancer	6.14e-06	3.53e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—AKT1—breast cancer	6.12e-06	3.52e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CA—breast cancer	6.04e-06	3.48e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MDM2—breast cancer	6.02e-06	3.47e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GPX1—breast cancer	6.02e-06	3.46e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—RAF1—breast cancer	6e-06	3.45e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—RELA—breast cancer	5.97e-06	3.44e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP1A1—breast cancer	5.96e-06	3.43e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ERBB2—breast cancer	5.93e-06	3.42e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	5.93e-06	3.41e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ERCC2—breast cancer	5.91e-06	3.4e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—COMT—breast cancer	5.87e-06	3.38e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CB—breast cancer	5.86e-06	3.37e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MTOR—breast cancer	5.86e-06	3.37e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTP1—breast cancer	5.84e-06	3.36e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SRC—breast cancer	5.82e-06	3.35e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HMOX1—breast cancer	5.76e-06	3.32e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ITPR1—breast cancer	5.75e-06	3.31e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—VEGFA—breast cancer	5.67e-06	3.26e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CXCL8—breast cancer	5.63e-06	3.24e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—STAT3—breast cancer	5.61e-06	3.23e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—HRAS—breast cancer	5.59e-06	3.22e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—MTHFR—breast cancer	5.55e-06	3.2e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ABCB1—breast cancer	5.53e-06	3.18e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN1B—breast cancer	5.5e-06	3.16e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—AKT1—breast cancer	5.44e-06	3.13e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TYMS—breast cancer	5.43e-06	3.13e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CASP3—breast cancer	5.39e-06	3.1e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL2—breast cancer	5.38e-06	3.1e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PLA2G4A—breast cancer	5.37e-06	3.09e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOR1—breast cancer	5.37e-06	3.09e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTM1—breast cancer	5.37e-06	3.09e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK3—breast cancer	5.36e-06	3.09e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL6—breast cancer	5.35e-06	3.08e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCND1—breast cancer	5.24e-06	3.02e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JUN—breast cancer	5.23e-06	3.01e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MYC—breast cancer	5.21e-06	3e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TGFB1—breast cancer	5.2e-06	2.99e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CTNNB1—breast cancer	5.19e-06	2.99e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GPX1—breast cancer	5.14e-06	2.96e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CAV1—breast cancer	5.12e-06	2.95e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EGFR—breast cancer	5.1e-06	2.94e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MMP9—breast cancer	5.09e-06	2.93e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP1A1—breast cancer	5.09e-06	2.93e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN1A—breast cancer	5.07e-06	2.92e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTEN—breast cancer	5.06e-06	2.91e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ERCC2—breast cancer	5.05e-06	2.91e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK8—breast cancer	4.95e-06	2.85e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—AKT1—breast cancer	4.94e-06	2.84e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.89e-06	2.82e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KRAS—breast cancer	4.82e-06	2.77e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—MTHFR—breast cancer	4.74e-06	2.73e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SRC—breast cancer	4.69e-06	2.7e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CG—breast cancer	4.67e-06	2.69e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VEGFA—breast cancer	4.57e-06	2.63e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STAT3—breast cancer	4.53e-06	2.61e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CA—breast cancer	4.43e-06	2.55e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CAV1—breast cancer	4.38e-06	2.52e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK3—breast cancer	4.32e-06	2.49e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—breast cancer	4.28e-06	2.46e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MYC—breast cancer	4.21e-06	2.42e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TGFB1—breast cancer	4.2e-06	2.42e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.18e-06	2.41e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EGFR—breast cancer	4.11e-06	2.37e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CD—breast cancer	4.1e-06	2.36e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HRAS—breast cancer	4.09e-06	2.36e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ALB—breast cancer	4.05e-06	2.33e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CG—breast cancer	3.99e-06	2.3e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL6—breast cancer	3.92e-06	2.26e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KRAS—breast cancer	3.89e-06	2.24e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NOS3—breast cancer	3.87e-06	2.23e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKT1—breast cancer	3.62e-06	2.08e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CB—breast cancer	3.57e-06	2.06e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CA—breast cancer	3.57e-06	2.06e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTGS2—breast cancer	3.54e-06	2.04e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CD—breast cancer	3.5e-06	2.02e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ALB—breast cancer	3.46e-06	1.99e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—breast cancer	3.45e-06	1.99e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NOS3—breast cancer	3.31e-06	1.91e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HRAS—breast cancer	3.3e-06	1.9e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL6—breast cancer	3.16e-06	1.82e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTEN—breast cancer	3.09e-06	1.78e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CB—breast cancer	3.05e-06	1.76e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTGS2—breast cancer	3.03e-06	1.74e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKT1—breast cancer	2.92e-06	1.68e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTEN—breast cancer	2.64e-06	1.52e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CA—breast cancer	2.18e-06	1.25e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CA—breast cancer	1.86e-06	1.07e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKT1—breast cancer	1.78e-06	1.02e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKT1—breast cancer	1.52e-06	8.76e-06	CbGpPWpGaD
